Pipeline Review: Emerging Drugs to Prevent Muscle Loss During GLP-1 Therapy
15-40% of GLP-1/GIP drug weight loss is lean muscle; emerging therapeutics including SARMs, myostatin/TGF-β inhibitors, and siRNA therapies aim to preserve muscle mass during treatment.
Quick Facts
What This Study Found
15-40% of incretin-induced weight loss is lean mass; pipeline solutions include SARMs, myostatin/TGF-β inhibitors, and siRNA; current limitations: parenteral delivery, short trials, sparse functional outcomes, FDA focus on total weight not composition.
Key Numbers
How They Did This
Review of emerging therapeutics pipeline for preserving lean mass during GLP-1/GIP agonist therapy.
Why This Research Matters
Muscle loss undermines the metabolic benefits of weight loss and increases frailty risk. The field urgently needs muscle-sparing co-therapies.
The Bigger Picture
The next frontier in obesity pharmacotherapy is not just losing more weight, but losing the right kind of weight — fat, not muscle.
What This Study Doesn't Tell Us
Most pipeline agents are early-stage. Functional muscle outcomes rarely measured. Regulatory path for muscle-preserving claims unclear.
Questions This Raises
- ?Which muscle-preserving agent will reach market first?
- ?Should regulatory endpoints be changed to include body composition?
- ?Can exercise + protein supplementation adequately substitute for pharmacological approaches?
Trust & Context
- Key Stat:
- 15-40% is muscle Up to 40% of weight lost on GLP-1/GIP drugs is lean muscle mass, driving urgent need for muscle-sparing co-therapies
- Evidence Grade:
- Pipeline review with preclinical and early clinical evidence. Most candidates are pre-approval.
- Study Age:
- Published in 2025.
- Original Title:
- Mitigating loss of lean muscle in GLP-1 and dual GLP-1/GIP agonists: Pipeline opportunities and limitations.
- Published In:
- Biochimica et biophysica acta. Molecular basis of disease, 1872(4), 168172 (2026)
- Database ID:
- RPEP-15294
Evidence Hierarchy
Frequently Asked Questions
Why does losing muscle matter during weight loss?
Muscle burns calories, improves blood sugar, and prevents falls. Losing 15-40% of weight as muscle undermines these benefits and increases frailty risk, especially in older adults.
What drugs could prevent muscle loss on GLP-1 therapy?
Several are in development: SARMs (anabolic agents), myostatin inhibitors like bimagrumab (block muscle-wasting signals), and siRNA therapies (silence muscle-degrading genes). None are approved yet for this use.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15294APA
Hierholzer, Justin; Benson, Harrison; Ewida, Heba A; Ahmed, Mahmoud Salama. (2026). Mitigating loss of lean muscle in GLP-1 and dual GLP-1/GIP agonists: Pipeline opportunities and limitations.. Biochimica et biophysica acta. Molecular basis of disease, 1872(4), 168172. https://doi.org/10.1016/j.bbadis.2026.168172
MLA
Hierholzer, Justin, et al. "Mitigating loss of lean muscle in GLP-1 and dual GLP-1/GIP agonists: Pipeline opportunities and limitations.." Biochimica et biophysica acta. Molecular basis of disease, 2026. https://doi.org/10.1016/j.bbadis.2026.168172
RethinkPeptides
RethinkPeptides Research Database. "Mitigating loss of lean muscle in GLP-1 and dual GLP-1/GIP a..." RPEP-15294. Retrieved from https://rethinkpeptides.com/research/hierholzer-2026-mitigating-loss-of-lean
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.